Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endo returns pain drug rights to Durect
Endo and Durect have recently completed a successful end-of-Phase II meeting with the FDA. Endo has notified Durect of its intention to terminate the licensing agreement entered into
Endo and Durect have recently completed a successful end-of-Phase II meeting with the FDA. Endo has notified Durect of its intention to terminate the licensing agreement entered into
The financing resulted in total gross proceeds of $200,000. The company intends to use the net proceeds from this private placement to satisfy certain amounts owed to Cato
ChemDiv and Nerviano Medical Sciences (NMS) have previously expanded their partnership to discover and develop potential anticancer agents. Under the terms of the collaboration, ChemDiv will receive a
Prevenar (also referred to as PCV7), the global standard in pneumococcal disease prevention for infants and young children, helps protect against the seven pneumococcal serotypes contained in the
The company has reported total revenues of E1.04 billion for 2008, an increase of 4.5%, compared to E993.8 million for 2007. Jean-Luc Belingard, chairman and CEO of Ipsen,
The decrease in net loss for the fourth quarter of 2008 is due primarily to a 45% decrease in operating expenses to $2.1 million from $3.9 million in
According to the company, the Waterlase MD Turbo offers significant upgrades, including a new handpiece with newly released software that recently received 510(k) clearance from the FDA. Other
Formal notice was received by Emergency Filtration Products (EFP) on February 26, 2009. Applied Nanoscience is a marketer and developer of nanotechnology-based filtration products to customers worldwide and
The company said that it is in negotiations to acquire a pharmacy in the Florida area to execute a definitive agreement regarding the pending acquisition of the pharmacy
Under the terms of the agreement, Novartis will pay Epistem an upfront cash payment of $4 million and will provide research funding for two years. Novartis has an